ææ°ã® Novartis AG ã®æ ªåŒãã¥ãŒã¹ã決ç®ãã¢ããªã¹ãè©äŸ¡ãéèŠãªååã远跡ã§ããŸãã
7æ2æ¥ã®Novartis AG (NVS) å€åãã¯3.39%äžæïŒå€åãã®èåŸã«ããèŠå
6æ24æ¥ã®Pfizer Inc (PFE) å€åãã¯3.16%äžèœïŒæè³å®¶ãç¥ã£ãŠããã¹ãæ å ±
6æ23æ¥ã®Novartis AG (NVS) çµå€ã¯3.04%äžæïŒäž»ãªæšé²èŠå ãæããã«ãããŸãã
6æ11æ¥ã®Novartis AG (NVS) å€åãã¯4.20%äžæïŒæè³å®¶ãç¥ã£ãŠããã¹ãæ å ±
6æ4æ¥ã®Novartis AG (NVS) çµå€ã¯3.12%äžæïŒå€åãã®èåŸã«ããäºå®
6æ1æ¥ã®Novartis AG (NVS) å€åãã¯3.14%äžèœïŒå®å šãªåæ
4æ2æ¥ã®Bristol-Myers Squibb Co (BMY) å€åãã¯3.58%äžèœïŒå®å šãªåæ
3æ11æ¥ã®Novartis AG (NVS) å€åãã¯3.16%äžèœïŒäž»ãªæšé²èŠå ãæããã«ãããŸãã